A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.

Gore, M; Oza, A; Rustin, G; Malfetano, J; Calvert, H; Clarke-Pearson, D; Carmichael, J; Ross, G; Beckman, R A; Fields, S Z

Gore, M; Oza, A; Rustin, G; Malfetano, J; Calvert, H; Clarke-Pearson, D; Carmichael, J; Ross, G; Beckman, R A; Fields, S Z.

Affiliation

Gore M; Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. martin.gore@rmh.nthames.nhs.uk

Eur J Cancer ; 38(1): 57-63, 2002 Jan.

Article in En | MEDLINE | ID: mdl-11750840

Subject(s)

Antineoplastic Agents/administration & dosage; Neoplasm Recurrence, Local/drug therapy; Ovarian Neoplasms/drug therapy; Topotecan/administration & dosage; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Female; Gastrointestinal Diseases/chemically induced; Hematologic Diseases/chemically induced; Humans; Infusions, Intravenous; Magnetic Resonance Imaging/methods; Middle Aged; Neoplasm Staging/methods; Tomography, X-Ray Computed/methods; Topotecan/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Ovarian Neoplasms / Topotecan / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2002 Type: Article Affiliation country: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links